Indication
Breast Cancer
1) First-line treatment of metastatic or recurrent breast cancer.
2) Second-line treatment of metastatic breast cancer after failure of standard chemotherapy.
Lung Cancer
1) First-line treatment of locally advanced or metastatic non-small cell lung cancer.
Ovarian cancer
1) First-line treatment in combination with other chemotherapeutic agents.
Benefit
The new formulation is free from toxic surfactant and allows significantly higher dosing of paclitaxel to the patients.
(The goal of polymeric micelle technology is to enhance solublization of water insoluble drugs to facilitate formulation of therapeutcally more effective products)
